Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 40Leukemia, Myeloid, Acute 35Lung Neoplasms 34Breast Neoplasms 32Multiple Myeloma 25Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 23Prostatic Neoplasms 21Pancreatic Neoplasms 20Carcinoma, Renal Cell 19Melanoma 18Lymphoma 16Urinary Bladder Neoplasms 15Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Myelodysplastic Syndromes 14Burkitt Lymphoma 13Lymphoma, Large B-Cell, Diffuse 11Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Glioma 10Fallopian Tube Neoplasms 10Mouth Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Hepatocellular 9Carcinoma 9Oropharyngeal Neoplasms 8Lymphoma, T-Cell 8

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Specimen Handling × 30 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡